ACTRT1

Across TCGA pan-cancer cohorts, ACTRT1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACTRT1 data layer compared with 13 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ACTRT1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACTRT1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, SARC, and STAD are the cancer types where ACTRT1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
SARC	OS	Median	All	0.164	0.839	<.001	12	view →
STAD	OS	Median	All	0.259	0.733	.004	12	view →
LUSC	OS	Median	IV	0.001	0.673	.014	12	view →
UCEC	DFS	Median	II,III,IV	0.873	0.436	.032	12	view →
COAD	OS	Median	II,III,IV	0.270	0.792	.003	9	view →
GBM	OS	Median	All	0.119	0.419	.004	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACTRT1–DLBC (DFS)

Open the DLBC breakdown →